US Patent 10064921 Botulinum toxin treatments of neurological and neuropsychiatric disorders
Patent 10064921 was granted and assigned to Allergan, Inc. on September, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+478 characters)
Article
Patent abstract
Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder.
Edits on 1 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Inventor Names
Andrew M. Blumenfeld0
Edits on 25 Mar, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 27 Sep, 2022
Golden AI
Infobox
Patent Citations Received
Edits on 8 Feb, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 29 Jan, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 22 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10064921 Botulinum toxin treatments of neurological and neuropsychiatric disorders
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10064921
Date of patent
September 4, 2018
Patent application number
15447770
Date Filed
March 2, 2017
Patent primary examiner
Find more entities like US Patent 10064921 Botulinum toxin treatments of neurological and neuropsychiatric disorders
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
